News
Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma
Regulatory News:
Abbas Hussain (56, British citizen) has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain
Abbas Hussain zum neuen Chief Executive Officer von Vifor Pharma ernannt
Regulatory News:
Abbas Hussain (56, britischer Staatsbürger) verfügt über eine mehr als 30-jährige erfolgreiche und internationale Karriere als Führungskraft im Gesundheitssektor. Von 2008 bis
Transgene: First Patient Enrolled in Expanded Phase II Clinical Trial of TG4001 + Avelumab Vs Avelumab Alone in Patients With HPV16-positive Anogenital Cancers
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that a first patient has
Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Pfizer Declares Third-Quarter 2021 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company’s common stock, payable September 7, 2021, to holders of the Common
Vifor Pharma to revise DIAMOND study, readout expected in H2 2021
Regulatory News:
Vifor Pharma Group today announced that the phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints, including a new primary endpoint of efficacy in
Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the first clinical site for the Phase 1/2 LuMIERE study of FAP-2286, its novel peptide-targeted radionuclide therapy and imaging agent
First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study will
Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2021
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth
Genus plc to Hold Capital Markets Event Today at 10:00 AM ET and Provide Update on its Porcine PRRSv Resistance Program
Genus plc (LSE: GNS), a leading global animal genetics company, is hosting a Capital Markets Event (CME) today at 10 AM ET, 3pm UK time. The CME will cover key strategic progress and initiatives
QIAGEN bringt dedizierte CRISPR-Produkte für schnelle und einfache Analyse der Auswirkungen von Genome Editing auf den Markt
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Einführung des QIAprep& CRISPR Kit und der CRISPR Q-Primer Solutions bekannt, die Forscher in die Lage versetzen, bearbeitetes
QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAprep& CRISPR Kit and CRISPR Q-Primer Solutions that allow researchers to analyze edited genetic material with
IMV Announces Annual and Special Meeting of Shareholders Voting Results
IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company, today announced the voting results from its annual and special meeting of shareholders held on
ICON Announces Pricing of Senior Secured Notes
ICON plc (NASDAQ: ICLR) (“ICON”) announced today in connection with the proposed acquisition by ICON of PRA Health Sciences, Inc. (“PRA”) pursuant to which Indigo Merger Sub, Inc., a wholly owned
Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia
Pfizer Inc. (NYSE: PFE) and The Academic Research Organization (ARO) from the Hospital Israelita Albert Einstein today announced that the New England Journal of Medicine has published positive
THERANEXUS : MINUTES OF THE COMBINED GENERAL MEETING OF 16 JUNE 2021
The combined general meeting of shareholders was held on 16 June 2021 at 10:00 am at the Etoile Business Center, 21-25 rue Balzac, 75008 Paris.
The general meeting adopted all the resolutions by a
Pfizer Invites Public to View and Listen to Webcast of Pfizer July 28 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, July 28, 2021. The
Novocure Initiates Usability Study for Flexible Torso Array
Novocure (NASDAQ: NVCR) today announced it has advanced a new, flexible torso array into a clinical usability study. The updated array will be tested by patients and their caregivers at four
ICON Shareholders Vote in Favour of All Resolutions at its Extraordinary General Meeting
ICON plc (NASDAQ: ICLR) (“ICON”), a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and
ICON Announces Private Offering of Senior Secured Notes
ICON plc (NASDAQ: ICLR) (“ICON”) announced today in connection with the proposed acquisition by ICON of PRA Health Sciences, Inc. (“PRA”) pursuant to which Indigo Merger Sub, Inc., a wholly owned
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company’s Board of Directors
Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announces that it has entered into an
Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders
Clovis Oncology, Inc. (NASDAQ:CLVS) (the “Company”) today announced partial results and the partial adjournment of its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). The Company
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies’ COVID-19 vaccine, 200
Sensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within